After lung-cancer chemoradiation, a second drug raised the harm without proving the extra benefit

Source: JAMA Oncology, published online October 29, phase 3 R-ALPS double-blind randomized trial, 553 patients at 42 centers in China. Primary study · DOI 10.1001/jamaoncol.2026.3918. Evidence: high-quality randomized study for the studied consolidation strategies. Clinical state: important oncology appraisal, not a direct comparison with all global standards of care.

More targeted treatment is tempting when a cancer remains likely to recur. R-ALPS tested the PD-L1 antibody benmelstobart after chemoradiation for unresectable stage III non-small-cell lung cancer, with or without the antiangiogenic drug anlotinib. The first stage compared both regimens against placebo; the additional stage strengthened the direct comparison between active regimens. This structure matters when interpreting the headline numbers.

In the first randomized stage, median independently assessed progression-free survival was 15.1 months for the combination, 9.7 for benmelstobart alone and 4.2 for placebo; both active regimens beat placebo. But when both randomized stages were pooled for the direct combination-versus-monotherapy question, median PFS was 17.4 versus 11.2 months, hazard ratio 0.82 (95% CI 0.63–1.08), p=0.12. The extra drug had not established superiority. Grade 3–5 treatment-related adverse events were 48.8% with the combination, 29.4% with benmelstobart alone and 19.7% with placebo; grade 5 treatment-related events were reported in 7.2%, 1.4% and 1.5%, respectively.

What this changes: A numerical median difference can coexist with uncertainty substantial enough that the randomized superiority claim fails. The excess serious and fatal toxicity is a patient-important counterweight. Existing treatment standards, cancer molecular subgroup, geography and subsequent therapies must be considered before changing care.